Last reviewed · How we verify
Placebo with enzalutamide
Enzalutamide is an androgen receptor inhibitor that blocks the binding and nuclear translocation of androgens, thereby suppressing androgen-driven prostate cancer cell growth.
Enzalutamide is an androgen receptor inhibitor that blocks the binding and nuclear translocation of androgens, thereby suppressing androgen-driven prostate cancer cell growth. Used for Metastatic castration-resistant prostate cancer, Non-metastatic castration-resistant prostate cancer, Metastatic hormone-sensitive prostate cancer.
At a glance
| Generic name | Placebo with enzalutamide |
|---|---|
| Sponsor | Pfizer |
| Drug class | Androgen receptor antagonist |
| Target | Androgen receptor (AR) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Enzalutamide competitively inhibits androgen receptor signaling by preventing ligand binding and blocking nuclear accumulation of the receptor. This mechanism is effective in castration-resistant prostate cancer where alternative androgen synthesis pathways may be active. The drug reduces proliferation of androgen-dependent cancer cells and can induce apoptosis.
Approved indications
- Metastatic castration-resistant prostate cancer
- Non-metastatic castration-resistant prostate cancer
- Metastatic hormone-sensitive prostate cancer
Common side effects
- Fatigue
- Hot flashes
- Diarrhea
- Musculoskeletal pain
- Headache
- Hypertension
- Seizures
Key clinical trials
- A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer. (PHASE3)
- Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991) (PHASE3)
- Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC (PHASE3)
- Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC (PHASE3)
- This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve. (PHASE3)
- A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer (PHASE2)
- Contributions to Hypertension With Androgen Deprivation Therapy (PHASE4)
- An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo with enzalutamide CI brief — competitive landscape report
- Placebo with enzalutamide updates RSS · CI watch RSS
- Pfizer portfolio CI